The governing board overseeing the National Institutes of Health research hospital voted unanimously on October 16, 2026, to rebuke Health Secretary Robert F. Kennedy Jr., accusing him of politicizing the facility's work and undermining public trust in science, according to The New York Times and KFF Health News. The formal pushback followed an unannounced October 5 visit by Kennedy to the agency's campus, where he held a ribbon-cutting ceremony for a new initiative focused on reported vaccine injuries and led a roundtable with patients.

During the NIH Clinical Center board's quarterly meeting on October 16, board chairman Jack Leslie opened the session by reading a six-minute statement addressing the secretary's actions, KFF Health News reported. While some commentary has characterized the dispute as a broader revolt among agency researchers—as reported by the Genetic Literacy Project—coverage from The New York Times and Becker's Hospital Review specifies that the documented institutional rebuke came from the hospital's governing board and focused on the appearance of scientific impartiality rather than an opposition to studying post-vaccination health problems.

Concerns Over Scientific Impartiality and Public Trust

In his statement to the board, Leslie emphasized that serious vaccine injuries are "rare but real" and agreed that rigorous scientific investigation into these conditions is warranted, according to The New York Times. However, he expressed concern that the public presentation of the October 5 launch could lead observers to believe the research had already reached a predetermined conclusion before any studies began.

During Kennedy's unannounced visit and subsequent roundtable discussion with people reporting post-vaccination health problems, the secretary shared a social-media video featuring signs that read "Vaccine Injured," according to Becker's Hospital Review. Leslie warned that framing the research in this manner creates a credibility dilemma for the hospital regardless of what the science ultimately shows.

According to The New York Times, Leslie argued that either positive or null findings could be discounted by the public. If researchers identify a link between a vaccine and an injury, critics might dismiss the findings as having been shaped by a health secretary known for criticizing vaccines. Conversely, if the data reveals no causal link, patients who believe they were harmed might view the clinic as a sham.

Administration officials defended the secretary's approach, stating that the goal is to support patients who feel ignored by the medical establishment. Kennedy has maintained that the federal government must not "dismiss or gaslight" families reporting adverse events, while Department of Health and Human Services (HHS) spokeswoman Emily Hilliard stated that the initiative would ensure individuals experiencing health problems after vaccination are taken seriously, The New York Times reported. Meanwhile, NIH Clinical Center CEO Jonathan Green assured the board that the clinic would require no new resources and that its studies would undergo the same scientific and ethical review applied to all other research at the hospital.

How the New NIH Vaccinology and Immunology Center Will Operate

On October 19, three days after the hospital board's vote, the National Institutes of Health (NIH) released a formal statement from NIH Director Jay Bhattacharya and National Institute of Allergy and Infectious Diseases (NIAID) Acting Director John H. Powers III outlining the structure of the new program.

The statement clarified that the agency is establishing a research study titled the Vaccinology and Immunology Center, marking its opening as October 5. Housed within NIAID's existing Vaccine Research Center clinic—which was originally established in 1999—the program will bring together physician-scientists, laboratory researchers, and patients at the NIH Clinical Center to examine individual immune responses and the biological mechanisms behind reported symptoms.

In their joint statement, Bhattacharya and Powers noted that Congress established the National Vaccine Injury Compensation Program in 1986, recognizing that while vaccines benefit many people, they can, like any medical intervention, cause adverse effects in some recipients. They also pointed to the experiences of Americans living with Long COVID, noting that infections can trigger long-term symptoms that are often indistinguishable from adverse events reported after vaccination.

Broader Federal Vaccine Policy Shifts

The debate at the NIH research hospital is occurring alongside wider shifts in federal vaccine oversight. On October 8, HHS announced a broader vaccine injury initiative that includes both the NIH clinical research effort and a proposal from the Centers for Medicare and Medicaid Services (CMS) to pay physicians for filing reports with the Vaccine Adverse Event Reporting System (VAERS), according to CIDRAP at the University of Minnesota.

Public health analysts noted in the CIDRAP report that existing monitoring systems already have an established track record of identifying rare side effects, such as linking a rare clotting disorder to the Johnson & Johnson COVID-19 vaccine in 2021. Because anyone can submit a report to VAERS, a submission alone does not verify that a vaccine caused a health problem. Analysts warned that offering financial incentives to increase VAERS submissions without corresponding verification could be mistaken by the public as evidence of widespread harm. They also noted that existing injury claims face a compensation backlog of two to three years, an issue not directly addressed by the new reporting proposals.

These policy adjustments come at a delicate moment for local public health infrastructure. According to KFF Health News, the United States has surpassed 4,000 measles cases and appears to have doubled the number of measles-related deaths compared to last year, leaving local health departments overwhelmed as Kennedy continues to publicly question the safety of routine immunizations such as the hepatitis B vaccine.

What This Means for Patients and Prospective Participants

For individuals experiencing complex health issues following either an infection or an immunization, the National Institutes of Health (NIH) emphasized that the new Vaccinology and Immunology Center is a structured clinical study rather than an open medical clinic.

Who is eligible to enroll in the NIH study, and how does access work?

The center will not accept walk-in patients or provide routine medical appointments to the general public. Instead, NIH is finalizing a formal study protocol and expects to launch enrollment before the end of 2026. The initial phase anticipates enrolling several hundred participants, focusing specifically on individuals experiencing the most serious adverse effects following vaccination or severe long-term symptoms following an infection. Accepted participants will enter through formal research enrollment and attend scheduled study visits. Prospective participants seeking information while the protocol is finalized can contact the NIH Clinical Center's Office of Patient Recruitment at 800-411-1222.

How will the hospital ensure scientific standards are maintained?

While specific study protocols and analytical methods are still being finalized by NIAID and NIH leadership, NIH Clinical Center CEO Jonathan Green stated that all studies conducted under the initiative will be subjected to the hospital's standard scientific and ethical review processes before research proceeds.

Sources